REVIVE THERAPEUTICS WKN: A2AP4F ISIN: CA7615161030 Kürzel: RVVTF Forum: Aktien Thema: Hauptdiskussion

Zwei Placements ? März und April, einmal 33,5 Millionen neue Aktien zu 0,0325 Euro je Aktie und einmal 16,4 Millionen neue Aktien zu 0,0325 Euro je Aktie. Ich befürchte, die fliegen den kleinen Spekulanten, auch hier in D, nach Ablauf der Holding-Period um die Ohren. Gibt auch einen Holder hier in D (März). Wird schon irgendwo gepusht ? Obacht.

https://investingnews.com.au/revive-therapeutics-announces-closing-of-second-tranche-of-brokered-private-placement Wird spannend 🙏🏼

Ob der einstieg lohnt.....

Denke leider eher, dass der ganze covid Kram bla bla ist, um Aufmerksamkeit zu bekommen. Nichts konkretes, was den Anstieg heute rechtfertigen könnte

Starker Anstieg

Interessant 👀 Und es läuft 😱 Aber bestimmt wieder so eine Canadier puscher Aktie☠ mit Garantie 🤕🥵🤯 Kopfschmerzen Besser Finger weg lassen

👀

http://www.globenewswire.com/news-release/2019/10/24/1935412/0/en/Revive-Therapeutics-Ltd-Announces-Results-for-Fiscal-Year-Ended-June-30-2019.html

Jemand hier ?

interessant! "I am pleased with how our focus on developing and commercializing novel cannabinoid-based therapies has evolved over this past year," said Craig Leon, Chief Executive Officer of Revive. "The value creating initiatives achieved for our medical cannabis and cannabinoid pharmaceuticals strategy such as the exclusive license and the research of cannabinoid-based therapies for liver diseases, the development of a unique delivery technology for cannabinoids, the relationships with scientific advisors, academia and industry, and the potential of future collaborations with companies seeking to develop and commercialize novel cannabinoid-based therapies effectively positions Revive in the medical cannabis and cannabinoid pharmaceuticals space for broad and large market opportunities." Over the past year Revive has been focused on developing novel therapies that target the endocannabinoid system and building a robust cannabinoid-based product pipeline which includes early stage research and development programs with the advancement of cannabinoid-based therapies for liver diseases and potentially late stage commercial opportunities with the development of a unique cannabinoid delivery system for the medical cannabis market. Revive continues to dedicate its resources in identifying and researching novel cannabinoid-based therapies and in developing its cannabinoid delivery technology for both near-term commercial opportunities in the medical cannabis market and long-term opportunities in the cannabinoid pharmaceuticals market.